It is reasonable to speculate that the expression levels of the targets of HX009, the ICs PD1 or its ligands, PD-L1/2, and CD47, in lymphoma could be important parameters that influence HX009 efficacy. This evidence concerns the gene PDCD1 and lymphoma.